Contribute Try STAT+ Today

The genomics pioneer who sequenced the human genome carved out a new niche just over a year ago, selling exhaustive $25,000 medical workups to apparently healthy people. Now Craig Venter’s trying to take one small piece of that business to a much wider audience — and to prove it’s worthwhile.

An early step in that direction came this month, when Venter’s company Human Longevity struck a deal with a life insurer to boost its $2,500 whole genome analysis product. For a discounted $1,400, customers and employees of the life insurer, MassMutual, can get every inch of their DNA scoured and then interpreted for what it means for their disease risk. It’s a way to “turn risks into opportunities to outsmart the diseases that may lie in your future,” Human Longevity’s website says of the product.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am curious: does their report include MTHFR variants and other genes impacting methylation and detoxification pathways?

Comments are closed.